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O6-methylguanine DNA methyltransferase (MGMT) is a DNA repair enzyme with the abil-
ity to protect cells from DNA mutations by removing alkyl groups from the O6 position of
guanine. Colon mucosa is exposed to the direct effects of environmental carcinogens and
therefore maintaining a proficient DNA repair system is very important to stay protected
against DNA mutagenesis. Loss of MGMT expression is almost exclusively associated
with methylation of CpG islands in the MGMT gene promoter region which is found in
approximately 40% of colorectal cancers. The role of MGMT loss in colorectal tumorige-
nesis is complex but numerous studies have documented methylation of this gene even
in the normal appearing mucosa as well as in aberrant crypt foci, suggesting that MGMT
methylation can be regarded as an early event or “field defect” in colon cancer neoplasia.
The focus of this perspective is the role of MGMT in different pathways of colorectal car-
cinogenesis as well as the implication of this molecule in treatment decisions in colorectal
cancer patients.
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INTRODUCTION
O6-methylguanine DNA methyltransferase (MGMT) is a ubiq-
uitously expressed DNA repair enzyme with a unique ability to
directly remove alkyl groups from the O6 position of guanine. O6-
alkylguanine adducts cause damage by mispairing with thymine
during replication leading to G:C to A:T transitions (1). Therefore
MGMT protects normal cells from exogenous carcinogens. For
example it has been shown that MGMT protects body against N-
nitroso compounds, known to induce colon cancer by methylating
the DNA (2). The downside is that MGMT with the same mech-
anism can protect cancer cells from alkylating chemotherapeutic
agents. Each MGMT molecule can only engage in one enzymatic
reaction since the active site of MGMT cannot be regenerated.
Therefore, upon performing its enzymatic reaction, MGMT is
targeted for ubiquitination and degradation (1). Because of this
“suicide” mechanism, a cell will have only limited resources to
repair abnormal adducts depending on the available numbers of
MGMT molecules and the rate of MGMT synthesis. This concept
raised many efforts to find an inhibitor for MGMT to be used in
clinical practice to overcome resistance to alkylating chemother-
apy; however, none of the inhibitors that have been identified
showed a clinical advantage in different clinical trials (3). This
is partly because of the exacerbation of the toxic side effects of
the alkylating drugs due to inactivation of MGMT in normal
tissues.
MGMT protein is encoded by MGMT gene located at chro-
mosome locus 10q26 (4). The MGMT gene has a CpG island
containing promoter and thus its expression is significantly reg-
ulated by DNA methylation which leads to epigenetic silencing
of the gene and loss of MGMT protein expression (1). The
most reliable method to evaluate MGMT methylation is a matter
of controversy. Methylation specific polymerase chain reaction
(MSP) is the most widely used technique with relatively high sen-
sitivity and specificity (5). However, the reliability of MSP is depen-
dent on good quality DNA, which is not typically obtainable from
formalin-fixed, paraffin-embedded (FFPE) specimens (6). On the
other hand, MSP fails to provide quantitative measurements on
MGMT methylation. These limitations constrain the implication
of MSP in the clinical setting. Pyrosequencing, combined bisulfite
restriction analysis (COBRA),MethyLight,Methylation Sensitive –
High Resolution Melting (MS-HRM), Methylation specific mul-
tiplex ligation-dependent probe amplification (MS-MLPA) are
other semiquantitative or quantitative methods that have been
used to evaluate MGMT promoter methylation (7, 8). A recent
study investigating the association between MGMT methylation
and protein expression showed that MGMT protein expression
assessed by immunohistochemistry (IHC) did not correlate with
methylation status of MGMT (assessed by MSP) suggesting that
MSP and IHC should not be used interchangeably (9).
There are 97 CpG sites present on the promoter region of
MGMT. Interestingly, these CpG sites do not equally contribute
to gene silencing as it has been shown that methylation among
these sites is not uniform. Extensive studies have been conducted
to map the specific CpG sites that can best predict gene silencing.
In one the recent studies, Everhard et al. found six isolated CpG
sites (CpGs −228,−186,+95,+113,+135, and +137) as well as
two CpG regions (−186 to −172, and +93 to +153), each with
a minimum of 81.5% of concordant results between methylation
and expression (10). Furthermore, an association between MGMT
methylation and the germline C to T SNP (rs16906252) within the
first exon of MGMT is observed in colorectal cancer and normal
colonic mucosa (11, 12).
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The impact of MGMT loss in carcinogenesis was first reported
in 1999 by Esteller et al. (5). Loss of MGMT expression due to
aberrant promoter methylation was shown in 40% of colorectal
cancers and gliomas and 25% of non-small cell lung carcinomas,
lymphomas, and head and neck carcinomas (5). One year later,
the same group documented a link between loss of MGMT and
G to A mutations in K-ras gene in colon cancer (13), which was
followed by a report showing the similar findings in gastric cancers
(14). Two other groups described an association between loss of
MGMT and G to A mutations in p53 gene in astrocytomas and
non-small cell lung cancers (15, 16). The link between MGMT loss
and G to A mutagenesis has been confirmed in subsequent studies
(17–19). However, the results of other studies did not support this
sequence of changes (12, 20, 21).
MGMT AND COLON CANCER
The role of MGMT loss in colorectal tumorigenesis is complex and
not well characterized. MGMT methylation has been detected in
the aberrant crypt foci, which are the earliest precursor lesions in
colon cancer development (22) suggesting that MGMT methyla-
tion is an early event in neoplastic pathway. Furthermore, low level
methylation of MGMT has been reported in normal appearing
colon mucosa in patients with a correspondingly MGMT methy-
lated tumor, as well as individuals without colon cancer (12, 18,
23–25). This finding is suggestive of a role for MGMT methylation
as a “field defect” in sporadic colon cancer carcinogenesis which
is defined as an area of molecularly abnormal tissue that precedes
and predisposes to the development of cancer (18). Therefore, it
has been proposed that MGMT status might be a useful marker
for early detection and risk assessment in sporadic colon cancers.
Two major pathways have been described in sporadic colorec-
tal cancers: the chromosomal instability (CIN) pathway and CpG
Island Methylator Phenotype (CIMP) pathway. The strong asso-
ciation of MGMT loss with CpG methylation links MGMT to the
CIMP pathway, which is associated with BRAF-V600E mutation
and MSI-high status (26, 27). In fact MGMT methylation has
been documented in their precursor lesions, sessile serrated ade-
noma/polyp (SSA/SSP) (28–31). It has been shown that serrated
adenomas with dysplasia are more associated with MGMT methy-
lation compared to hyperplastic polyps and serrated adenomas
without dysplasia (31). A recent study reported MGMT methy-
lation in 46.7% of microvesicular hyperplastic polyps (MVHP),
60% of SSA/SSP without dysplasia, and 75% of SSA/SSP with dys-
plasia (32). In supporting of the contribution of MGMT protein in
MSI-H pathway of CRC neoplasia, Svrcek et al. reported that field
defects resulted from MGMT loss are more frequently associated
with MSI-H than microsatellite-stable (MSS) colorectal cancers
and concluded that methylation tolerance may represent a cru-
cial initiating step prior to MMR deficiency in the development of
MSI-H CRC (24).
On the other hand, the association of MGMT loss with G to
A transition in K-ras and p53 mutated genes, links MGMT to
the CIN pathway of colorectal cancers which is characteristically
MSS or -low (MSI-L) and CIMP-low (17, 33–35). The associa-
tion of MGMT with K-ras in the context of MSS/MSI-L CRCs
are not straight forward. For example, a recent study on 776
CRCs revealed that K-ras mutated carcinomas that are associated
with MGMT methylation, more frequently develop in contiguity
with a residual polyp and are associated with different MSI sta-
tus (36). Jass has suggested a “fusion pathway” with overlapping
features from the two major colorectal cancer pathways in which
MGMT serves as a “cross-over” point (37). He hypothesized that
the “fusion” of the hyperproliferation and crypt fission that char-
acterize adenomas with the inhibition of apoptosis that has been
linked with serrated polyps may generate lesions with enhanced
aggressiveness. The presence of p53 mutation (likely associated
with MGMT methylation) in some of the serrated polyps with
dysplasia provides an example of this link (37). Another possi-
ble link between these two pathways is villous adenoma which,
on one hand, is thought to represent an advance lesion in CIN
pathway and is frequently associated with K-ras mutation (38).
On the other hand, this lesion has morphologic resemblance to
the traditional serrated adenoma (TSA) and also harbors K-ras
mutation in a subset of cases, likely in association with MGMT
methylation (35, 37, 39). Therefore, it has been suggested that
villous adenoma may represent a bridge between the two path-
ways. Despite evidence for involvement of MGMT in colon cancer
carcinogenesis, previous studies fail to show any prognostic sig-
nificance of MGMT methylation (or loss of MGMT) in colorectal
cancers (33, 40, 41).
MGMT IN TREATMENT OF COLORECTAL CANCERS
The role of MGMT in response to alkylating chemotherapeutic
agents is well studied in glioma patients treated with temazolamide
(42, 43). Based on these studies, it is well established that the
patients with promoter methylation and loss of MGMT expres-
sion have much better response to chemotherapy and also longer
progression free and overall survival while the intact expression of
MGMT is predictive of a poor response to treatment and worse
overall survival (7, 44, 45). As it discussed earlier (see above) this
effect is most likely due to the protective function of MGMT
against alkylating agents in cancer cells. The significance of MGMT
expression in colorectal cancers is less investigated. One of the early
studies revealed that CRC patients with unmethylated MGMT pro-
moters who had been treated with chemotherapy were found to
have a 5.3-fold greater risk of recurrence than those who had no
exposure to chemotherapy (46). The exact mechanism for this
finding is not understood as 5FU is an antimetabolite and does
not function through alkylation of DNA. Regardless, this find-
ing suggests that CRC patients with intact MGMT expression
are not good candidates for 5FU adjuvant chemotherapy. Prior
clinical studies did not show a benefit for using alkylating agents
in treatment of colorectal cancer. However, given the effect of
MGMT loss in sensitizing cancer cells to alkylating agents, recently
several attempts were made to select suitable patients for these
medications. In a phase II clinical trial study with dacarbazine in
metastatic CRC patients who had failed standard therapies, objec-
tive clinical response was limited to those patients with MGMT
methylation (47). Similar findings were seen in metastatic patients
with MGMT methylation who were treated with single agent
Temozolomide (48). This data opens a new window for an effec-
tive treatment in patients with colon cancer who are deficient in
MGMT and represent an example of a personalized approach in
treatment of cancers.
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CONCLUSION
Colorectal cancer is a heterogeneous disease arising in asso-
ciation with abnormalities in different molecular pathways.
The fine dissection of molecular events is necessary to estab-
lish molecular signatures that can correctly classify CRCs and
reliably predict tumor behavior and prognosis. This article
is a part of an attempt to put together our current knowl-
edge about molecular mechanisms in CRC under the title of
“Toward molecular classification of colorectal cancer.” The role
of MGMT protein in colorectal carcinogenesis is rather com-
plex and poorly understood. However, based on the available data
there are grounds to believe that MGMT plays an important role
in development of CRC and may represent a bridge between
different molecular pathways. Further studies are required to
shed light on the contribution of this molecule in colorectal
neoplasia.
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